One of the most important factors in the development of a reliable assay is the quality of the gold conjugate. At BBI Solutions, we use the highest quality grades of gold nanoparticles and apply our unique conjugation protocol to deliver an optimised product that meets the demands of your assay. Whether you are looking to bind gold to a specific antibody, and need a custom conjugation, or off the shelf products, BBI can help and deliver.
Choice & Flexibility
Our core competencies include a comprehensive suite of reagents with custom development options, lateral flow development, diagnostic manufacturing services and smartphone reader technologies.
Quality System Certification
Each site follows strict Quality Control and product release protocols, which coupled with effective Quality Assurance processes ensure our products meet stringent product quality, safety and customer requirements.
Innovation is at the heart of our operations. The extensive breadth and depth of our products and services portfolio is testimony to the ongoing investment in our people and facilities.
Experience & Trust
BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immuno-diagnostics reagents.
The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.
Novarum™ technology transforms a smartphone into a diagnostic test reader, empowering users to read and share the results of rapid tests from the point of care. Our pioneering technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers, lab researchers and primary care clinicians to specialist practices as part of a mobile eco-system.